Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Terns Pharmaceuticals, Inc. Banner

Terns Pharmaceuticals, Inc.

TERN Stock Analysis

Page title

Section title

About Terns Pharmaceuticals, Inc.

Biotechnology
Healthcare

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH...

Terns Pharmaceuticals, Inc. Key Metrics

Market Cap
$862M
52 Weeks Low
$3.26
52 Weeks High
$11.40
P/B
3.48x
P/E
-7.93x
P/S
652.11x

Upcoming Events

    TERN Analyst Forecasts

    ‌
    ‌

    TERN Financials

    TERN Income Statement Key Metrics

    • Revenue(TTM)1.32 M
    • Gross Profit(TTM)404,000
    • EBITDA(TTM)-107.31 M
    • Net Income(TTM)-95.90 M
    • EPS Diluted(TTM)-1.3199999999999998

    Decode TERN's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    TERN earnings and revenue history

    TERN Return on Equity

    See how efficiently TERN generates profit for it's shareholders.

    -35.33%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of TERN (-0.353) is higher than the average of its peers (-0.748).

    Return on Equity Growth

    TERN's Return on Equity has shown poor growth over the past 10 years, increasing by only 6.27%.

    TERN Revenue Growth

    See how TERN has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    TERN's revenue has shown poor growth over the past 10 years, increasing by only 0%.